Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Landiolol versus standard of care in septic shock with hypercontractility (mortality prevention)
2020-002671-34Phase 3Active
- Sponsor
- CHU Amiens-Picardie
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in septic shock comparing Landiolol plus standard of care with Standard of care (2 arms). Primary endpoint: 28-day all-cause mortality. Started Jul 2020; status: active.
02
Drugs
landiolol
03
Conditions
septic shock
Beyond the preview
Go deeper on 2020-002671-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002671-34.